Publication | Closed Access

Design and synthesis of new norfloxacin-1,3,4-oxadiazole hybrids as antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA)

Antibacterial AgentsMethicillin-resistant Staphylococcus AureusAntibioticsMedicineNew Norfloxacin-1,3,4-oxadiazole HybridsAntibacterial AgentAntimicrobial ChemotherapyAntimicrobial CompoundPharmacologyAntimicrobial ResistanceDrug Resistance